[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:myelodysplastic-syndrome:hiv-infection":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Myelodysplastic Syndrome","HIV Infection",3,[8,16,23],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05470491","Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:17:35.666428Z","2026-05-05T02:43:29.587324Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT03314974","Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders",[20],"Phase 2","2026-08-26T02:16:14.341106Z","2026-05-05T02:43:28.206546Z",{"nct_id":24,"title":25,"phases":26,"status":27,"updated_at":28,"content_modified":29},"NCT07646821","A Phase 1b\u002F2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in Newly Diagnosed MDS\u002FAML (≥ 10% Blasts) With TP53 Mutations",[12],"NOT_YET_RECRUITING","2026-08-26T02:16:47.762107Z","2026-06-16T05:54:07.902931Z"]